|
Release date:
April 28, 2006
Available for credit through:
(Accrediation Expired)
Program completion time:
1 Hour
Program Description:
Neutropenia is the major dose-limiting toxicity associated with cancer chemotherapy and febrile neutropenia is associated with considerable morbidity, mortality, and cost. Colony Stimulating Factors, or CSFs are used to reduce the severity and duration of chemotherapy-induced neutropenia and diminish the risk of febrile neutropenia and infection for patients receiving chemotherapy. The risk of neutropenia varies depending on the agent used and dose delivered. Predictive factors of febrile neutropenia have been identified for several types of malignancies. Identification of these risk factors when chemotherapy is planned can support the appropriate use of CSFs to reduce the risk of febrile neutropenia for patients. Our expert panel will review the efficacy and appropriate use of myeloid growth factors for the prevention of chemotherapy-induced neutropenia and febrile neutropenia, discuss available guidelines for the use of CSFs to prevent febrile neutropenia, and use patient case studies to highlight issues with the administration of CSFs.
Target Audience:
This activity is intended for medical oncologists, hematologists, and other physician specialties involved in the management of neutropenia.
Learning Objectives:
- Discuss the efficacy and appropriate use of myeloid growth factors for the prevention of chemotherapy-induced neutropenia and febrile neutropenia in light of recently published data
- Identify patients at risk for the development of chemotherapy-associated febrile neutropenia
- Describe recommendations for primary prophylaxis of febrile neutropenia using myeloid growth factors
- Interpret and demonstrate the application of myeloid growth factor clinical guidelines for specific oncology patient cases
Disclaimer
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Amgen, any other manufacturer of pharmaceuticals, ArcMesa Educators, or Scinexa, LLC.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
|
|
